Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
1.3700
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 10th, 6:45 AM EDT
Detailed Quote
Previous Close
1.370
Open
-
Bid
1.090
Ask
1.100
Day's Range
N/A - N/A
52 Week Range
0.6500 - 26.25
Volume
343,746
Market Cap
199.99M
PE Ratio (TTM)
-0.2383
EPS (TTM)
-5.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,253,792
Chart
About Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
Citius Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutic products for critical care and cancer treatment. The company primarily specializes in the formulation and commercialization of medical products that aim to address unmet medical needs in the areas of oncology and critical care medicine. Citius is actively engaged in advancing its product pipeline through clinical trials, emphasizing the development of safe and effective therapies to improve patient outcomes. The company's commitment to research and development positions it as a key player in the pharmaceutical landscape, aiming to provide new treatment options for healthcare providers and patients alike. Read More
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares are trading higher Monday after the company announced it entered into a distribution services agreement with Cardinal Health.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five months.
